Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | recruiting | Phase 3 | 800 | GlaxoSmithKlineINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | recruiting | Phase 3 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT07379047 | Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)(GISTAR-1) | recruiting | Phase 2 / Phase 3 | 255 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Jun 10, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib(INSIGHT) | active not recruiting | Phase 3 | 54 | Deciphera Pharmaceuticals, LLCINDUSTRY | 15 | Dec 17, 2025 | clinicaltrials |
| NCT04409223 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | terminated | Phase 3 | 185 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02260505 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)(ImadGist) | completed | Phase 3 | 136 | Centre Leon BerardOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05970900 | Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST(PIRKER) | not yet recruiting | Phase 3 | 23 | Fujian Medical University Union HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT00812240 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | terminated | Phase 3 | 335 | AB ScienceINDUSTRY | 3 | Feb 1, 2023 | clinicaltrials |
| NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies(INVICTUS) | completed | Phase 3 | 129 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Nov 21, 2022 | clinicaltrials |
| NCT03465722 | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | completed | Phase 3 | 476 | Blueprint Medicines CorporationINDUSTRY | 18 | Oct 6, 2022 | clinicaltrials |
| NCT04761172 | NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours | unknown | Phase 2 / Phase 3 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01271712 | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)(GRID) | completed | Phase 3 | 199 | BayerINDUSTRY | 17 | Jan 29, 2021 | clinicaltrials |
| NCT01694277 | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib | completed | Phase 3 | 258 | AB ScienceINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT03426722 | L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors | completed | Phase 3 | 4 | Asan Medical CenterOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT01151852 | Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT | completed | Phase 3 | 81 | Asan Medical CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00103168 | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor | completed | Phase 3 | 908 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 9, 2018 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00324987 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor(S0502) | terminated | Phase 3 | 12 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2017 | clinicaltrials |
| NCT01289028 | Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. | completed | Phase 3 | 125 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 2, 2017 | clinicaltrials |
| NCT02866045 | EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs | unknown | Phase 3 | 104 | Unity Health TorontoOTHER | 1 | Aug 15, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01462994 | Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) | completed | Phase 3 | 25 | Technical University of MunichOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT02576080 | Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index(GIGIST) | unknown | Phase 3 | 80 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Oct 15, 2015 | clinicaltrials |
| NCT00293124 | Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | completed | Phase 3 | 125 | Central European Cooperative Oncology GroupOTHER | 10 | Aug 13, 2015 | clinicaltrials |
| NCT00009906 | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | terminated | Phase 3 | 748 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00685828 | Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor | unknown | Phase 3 | 946 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jul 4, 2014 | clinicaltrials |
| NCT02103322 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions | completed | Phase 2 / Phase 3 | 48 | Amneal Pharmaceuticals, LLCINDUSTRY | 1 | Jun 27, 2014 | clinicaltrials |
| NCT00751036 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg(MACS0375) | terminated | Phase 3 | 94 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 26, 2014 | clinicaltrials |
| NCT00367861 | Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance | completed | Phase 3 | 564 | Centre Leon BerardOTHER | 1 | Feb 24, 2014 | clinicaltrials |
| NCT01031628 | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | terminated | Phase 3 | 5 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00041197 | Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery | completed | Phase 3 | 732 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00688766 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | terminated | Phase 3 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00956072 | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | terminated | Phase 3 | 12 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00471328 | Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib(ENEST) | completed | Phase 3 | 248 | Novartis PharmaceuticalsINDUSTRY | 13 | Jun 12, 2012 | clinicaltrials |
| NCT00372567 | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | terminated | Phase 3 | 69 | PfizerINDUSTRY | 7 | Mar 17, 2011 | clinicaltrials |
| NCT00075218 | A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) | completed | Phase 3 | 361 | PfizerINDUSTRY | 11 | Sep 28, 2009 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials